BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34938296)

  • 1. Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection.
    Lin A; Yan WH
    Front Immunol; 2021; 12():788769. PubMed ID: 34938296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection.
    Littera R; Chessa L; Deidda S; Angioni G; Campagna M; Lai S; Melis M; Cipri S; Firinu D; Santus S; Lai A; Porcella R; Rassu S; Meloni F; Schirru D; Cordeddu W; Kowalik MA; Ragatzu P; Vacca M; Cannas F; Alba F; Carta MG; Del Giacco S; Restivo A; Deidda S; Palimodde A; Congera P; Perra R; Orrù G; Pes F; Loi M; Murru C; Urru E; Onali S; Coghe F; Giglio S; Perra A
    PLoS One; 2021; 16(8):e0255608. PubMed ID: 34352002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated frequencies of CD14
    Xue G; Jiang M; Zhao R; Le A; Li J
    Aging (Albany NY); 2021 Feb; 13(5):6236-6246. PubMed ID: 33640878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of HLA-G in tumors and upon COVID-19 infection.
    Seliger B
    Hum Immunol; 2024 May; 85(3):110792. PubMed ID: 38555250
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis.
    Boumaza A; Gay L; Mezouar S; Bestion E; Diallo AB; Michel M; Desnues B; Raoult D; La Scola B; Halfon P; Vitte J; Olive D; Mege JL
    J Infect Dis; 2021 Aug; 224(3):395-406. PubMed ID: 33493287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of pulmonary HLA-G expression by SARS-CoV-2 infection.
    Seliger B; Jasinski-Bergner S; Massa C; Mueller A; Biehl K; Yang B; Bachmann M; Jonigk D; Eichhorn P; Hartmann A; Wickenhauser C; Bauer M
    Cell Mol Life Sci; 2022 Nov; 79(11):582. PubMed ID: 36334153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic SARS-CoV-2-Specific Immunity in Critically Ill Patients With Hypertension.
    Zeng Q; Li YZ; Dong SY; Chen ZT; Gao XY; Zhang H; Huang G; Xu Y
    Front Immunol; 2020; 11():596684. PubMed ID: 33362779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 coronavirus vaccine T cell epitope prediction analysis based on distributions of HLA class I loci (HLA-A, -B, -C) across global populations.
    Cun Y; Li C; Shi L; Sun M; Dai S; Sun L; Shi L; Yao Y
    Hum Vaccin Immunother; 2021 Apr; 17(4):1097-1108. PubMed ID: 33175614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overlapping but Disparate Inflammatory and Immunosuppressive Responses to SARS-CoV-2 and Bacterial Sepsis: An Immunological Time Course Analysis.
    Loftus TJ; Ungaro R; Dirain M; Efron PA; Mazer MB; Remy KE; Hotchkiss RS; Zhong L; Bacher R; Starostik P; Moldawer LL; Brakenridge SC
    Front Immunol; 2021; 12():792448. PubMed ID: 34956225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 Nsp13 encodes for an HLA-E-stabilizing peptide that abrogates inhibition of NKG2A-expressing NK cells.
    Hammer Q; Dunst J; Christ W; Picarazzi F; Wendorff M; Momayyezi P; Huhn O; Netskar HK; Maleki KT; García M; Sekine T; Sohlberg E; Azzimato V; Aouadi M; ; ; Degenhardt F; Franke A; Spallotta F; Mori M; Michaëlsson J; Björkström NK; Rückert T; Romagnani C; Horowitz A; Klingström J; Ljunggren HG; Malmberg KJ
    Cell Rep; 2022 Mar; 38(10):110503. PubMed ID: 35235832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activating Killer-Cell Immunoglobulin-Like Receptors Are Associated With the Severity of Coronavirus Disease 2019.
    Bernal E; Gimeno L; Alcaraz MJ; Quadeer AA; Moreno M; Martínez-Sánchez MV; Campillo JA; Gomez JM; Pelaez A; García E; Herranz M; Hernández-Olivo M; Martínez-Alfaro E; Alcaraz A; Muñoz Á; Cano A; McKay MR; Muro M; Minguela A
    J Infect Dis; 2021 Jul; 224(2):229-240. PubMed ID: 33928374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HLA-G in human early pregnancy: control of uterine immune cell activation and likely vascular remodeling.
    Le Bouteiller P
    Biomed J; 2015; 38(1):32-8. PubMed ID: 25163504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E.
    Zidi I
    Hum Immunol; 2020 Dec; 81(12):697-701. PubMed ID: 33046268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8 T cell epitope generation toward the continually mutating SARS-CoV-2 spike protein in genetically diverse human population: Implications for disease control and prevention.
    Guo E; Guo H
    PLoS One; 2020; 15(12):e0239566. PubMed ID: 33301503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune characterization of a Colombian family cluster with SARS-CoV-2 infection.
    Aguilar-Jiménez W; Flórez-Álvarez L; Rincón DS; Marín-Palma D; Sánchez-Martínez A; Martínez J; Zapata MI; Loaiza JD; Cárdenas C; Guzmán F; Velilla PA; Taborda NA; Zapata W; Hernández JC; Díaz FJ; Rugeles MT
    Biomedica; 2021 Oct; 41(Sp. 2):86-102. PubMed ID: 34669281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistent High Percentage of HLA-DR
    Du J; Wei L; Li G; Hua M; Sun Y; Wang D; Han K; Yan Y; Song C; Song R; Zhang H; Han J; Liu J; Kong Y
    Front Immunol; 2021; 12():735125. PubMed ID: 34567001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic T cell epitopes of SARS-CoV-2 are recognized by circulating memory and naïve CD8 T cells of unexposed individuals.
    Quiros-Fernandez I; Poorebrahim M; Fakhr E; Cid-Arregui A
    EBioMedicine; 2021 Oct; 72():103610. PubMed ID: 34627082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cellular immune states in SARS-CoV-2-induced disease.
    Mortezaee K; Majidpoor J
    Front Immunol; 2022; 13():1016304. PubMed ID: 36505442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural Killer Cells in SARS-CoV-2 Infection: Pathophysiology and Therapeutic Implications.
    Di Vito C; Calcaterra F; Coianiz N; Terzoli S; Voza A; Mikulak J; Della Bella S; Mavilio D
    Front Immunol; 2022; 13():888248. PubMed ID: 35844604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent SARS-CoV-2-Specific T Cell Immunity and Low Anaphylatoxin Levels Correlate With Mild Disease Progression in COVID-19 Patients.
    Lafon E; Diem G; Witting C; Zaderer V; Bellmann-Weiler RM; Reindl M; Bauer A; Griesmacher A; Fux V; Hoermann G; Miller C; Zabernigg A; Wöll E; Wilflingseder D; Lass-Flörl C; Posch W
    Front Immunol; 2021; 12():684014. PubMed ID: 34194438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.